Profounda receives FDA Orphan Drug Designation for miltefosine for treating Primary Amebic Meningoencephalitis (PAM)
Profounda, Inc. announced Friday that it has received, the US Food and Drug Administration’s (FDA) Orphan Drug Designation for the treatment of Primary Amebic Meningoencephalitis (PAM) with miltefosine. More...
Impavido to treat leishmaniasis receives FDA approval
PRESS RELEASE The U.S. Food and Drug Administration today approved Impavido (miltefosine) to treat a tropical disease called leishmaniasis. Phlebotomus papatasi sand flyImage/CDC Leishmaniasis is a disease caused More...
